Actively Recruiting
Phase 2 Study of Venetoclax Combined With Chemotherapy for Children With Acute Myeloid Leukemia
Led by St. Jude Children's Research Hospital · Updated on 2026-09-17
70
Participants Needed
10
Research Sites
378 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and activity of venetoclax combined with standard chemotherapy in children newly diagnosed with acute myeloid leukemia AML. This phase 2 study aims to determine how well patients tolerate this combination and how many achieve minimal residual disease MRD negativity after the first induction therapy. Secondary goals include measuring rates of complete remission, event-free survival, and overall survival. Treatment varies based on genetic risk and response. Venetoclax is given orally with each therapy course. Low-risk patients receive four chemotherapy courses, intermediate-risk five, and high-risk patients two or three courses followed by possible stem cell transplantation. Chemotherapy drugs include cytarabine, daunorubicin, etoposide, gemtuzumab ozogamicin, mitoxantrone, fludarabine, idarubicin, azacitidine, and gilteritinib for patients with FLT3 activation, with schedules detailed for each risk group. Participants undergo various assessments including minimal residual disease testing by flow cytometry at day 29 after induction, monitoring for adverse events during therapy courses, and long-term follow-up for event-free and overall survival up to three years. Safety and treatment response are closely monitored throughout, with total participation lasting until study completion or as defined by individual treatment courses and follow-up periods.
CONDITIONS
Brief Title
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
Research Team
H
Hiroto Inaba, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here